Multiple Myeloma
📧 Sign up to get email alerts when something new happens for Multiple Myeloma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS withdrawal · 2024-07-10Clinical Trial Update: Selinexor and Lenalidomide for Consolidation and Maintenance Treatment in Multiple Myeloma Post-transplant [Phase 2]
This update reports the withdrawal of a Phase 2 trial evaluating selinexor plus lenalidomide as consolidation and maintenance after stem cel…
-
CLINICAL_TRIALS withdrawal · 2024-07-03Clinical Trial Update: Pembrolizumab as Salvage Therapy for the Treatment of Multiple Myeloma in Patients Progressing on CAR-T Cell Therapy [Phase 2]
A Phase 2 trial evaluating pembrolizumab as salvage therapy for plasma cell myeloma patients progressing after CAR-T therapy has been withdr…
-
CLINICAL_TRIALS withdrawal · 2024-05-31Clinical Trial Update: A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) [Phase 3]
A Phase 3 trial evaluating alnuctamab versus standard-of-care regimens in relapsed or refractory multiple myeloma has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2024-05-06Clinical Trial Update: Testing Nivolumab and BMS-986016 (Relatlimab) as Potentially Targeting Treatment in Cancers That Are LAG-3+ and Have Mismatch Repair Deficiency (MATCH - Subprotocol Z1M) [Phase 2]
A Phase 2 MATCH subprotocol trial testing nivolumab with relatlimab (BMS-986016) for LAG-3 positive tumors with mismatch repair deficiency h…
-
CLINICAL_TRIALS withdrawal · 2024-05-01Clinical Trial Update: CART-BCMA/CS1 in Treating Patients With Relapsed or Refractory Multiple Myeloma [Phase 1]
A Phase 1 clinical trial evaluating CART-BCMA/CS1 for relapsed or refractory multiple myeloma has been withdrawn.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS withdrawal · 2024-04-26Clinical Trial Update: Mycobiome Supporting Diet to Reduce GI Toxicity Associated With ASCT [NA]
A clinical trial evaluating a mycobiome-supported diet to reduce GI toxicity during autologous stem cell transplant for multiple myeloma has…
-
EMA withdrawal · 2023-12-15EMA confirms recommendation for non-renewal of authorisation of multiple myeloma medicine Blenrep
EU CHMP confirmed recommendation not to renew the conditional marketing authorisation for Blenrep (belantamab mafodotin) due to lack of conf…
-
EMA withdrawal · 2023-09-15EMA recommends non-renewal of authorisation of multiple myeloma medicine Blenrep
EMA recommends non-renewal of the marketing authorisation for Blenrep (belantamab mafodotin) for multiple myeloma.
-
EMA withdrawal · 2023-07-10EMA Withdrawn: Lenalidomide Krka d.d. (lenalidomide hydrochloride hydrate) — Krka, d.d., Novo mesto
The EMA withdrew lenalidomide hydrochloride hydrate (Krka) from the market for multiple indications including multiple myeloma, follicular l…
-
CLINICAL_TRIALS withdrawal · 2023-04-28Clinical Trial Update: Assessment of Bortezomib (Alvocade ®) Efficacy and Safety in Newly Diagnosed Multiple Myeloma Patients [Phase 4]
Phase 4 trial assessing bortezomib (Alvocade) in newly diagnosed multiple myeloma was withdrawn.
-
EMA withdrawal · 2022-12-15EMA Withdrawn: IntronA (interferon alfa-2b) — Merck Sharp & Dohme B.V.
The European Medicines Agency has withdrawn IntronA (interferon alfa-2b) from the market.
-
CLINICAL_TRIALS withdrawal · 2022-05-03Clinical Trial Update: A Multicenter In-class Transition Study of Ixazomib Combined With Pomalidomide and Dexamethasone or With Lenalidomide and Dexamethasone in Adults With Relapsed/Refractory Multiple Myeloma [Phase 4]
Phase 4 multicenter trial investigating ixazomib with pomalidomide or with lenalidomide and dexamethasone in relapsed/refractory multiple my…
-
CLINICAL_TRIALS withdrawal · 2021-07-09Clinical Trial Update: Carfilzomib, Daratumumab, Lenalidomide and Dexamethasone as First Line Treatment in Multiple Myeloma [Phase 3]
Phase 3 trial of Carfilzomib, Daratumumab, Lenalidomide and Dexamethasone for first-line treatment in multiple myeloma was withdrawn.
-
EMA withdrawal · 2020-07-27EMA Application withdrawn: Doxorubicin Hydrochloride Tillomed (doxorubicin hydrochloride) — Laboratorios Tillomed Spain S.L.U
The EMA withdrew the application for doxorubicin hydrochloride from Laboratorios Tillomed Spain S.L.U. for several cancer indications includ…
-
CLINICAL_TRIALS withdrawal · 2019-01-28Clinical Trial Update: 2017-03: A Single-Arm, Open-label Study of Anti-Signaling Lymphocytic Activation Molecule F7 (Anti-SLAMF7) Monoclonal Antibody (mAb) Therapy After Autologous Stem Cell Transplant in Patients With Multiple Myeloma [Phase 2]
Phase 2, single-arm open-label trial of an anti-SLAMF7 monoclonal antibody after autologous stem cell transplant in patients with multiple m…
-
CLINICAL_TRIALS withdrawal · 2018-07-02Clinical Trial Update: Simvastatin in Overcoming Chemotherapy Resistance in Patients With Relapsed or Refractory Multiple Myeloma [EARLY_Phase 1]
An early-phase study evaluating simvastatin to overcome chemotherapy resistance in relapsed or refractory multiple myeloma has been withdraw…
-
CLINICAL_TRIALS withdrawal · 2018-05-14Clinical Trial Update: Paclitaxel,Cyclophosphamide and Dexamethasone for Relapsed or Refractory Multiple Myeloma [Phase 2]
A Phase 2 trial evaluating Paclitaxel, Cyclophosphamide, and Dexamethasone for relapsed or refractory multiple myeloma has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2018-04-10Clinical Trial Update: Continuous Lenalidomide Therapy Versus Observation Following Induction Without Lenalidomide, Pomalidomide or Thalidomide in Myeloma [Phase 3]
Phase 3 trial evaluating continuous lenalidomide therapy versus observation after induction without lenalidomide, pomalidomide or thalidomid…
-
CLINICAL_TRIALS withdrawal · 2017-12-13Clinical Trial Update: Melphalan, Total Marrow Irradiation, and Autologous Stem Cell Transplantation in Treating Patients With High-Risk Multiple Myeloma [Phase 1, Phase 2]
The Phase 1/2 trial evaluating melphalan with total marrow irradiation and autologous stem cell transplantation for high-risk multiple myelo…
-
CLINICAL_TRIALS withdrawal · 2017-08-28Clinical Trial Update: Early Patient Access Single Named Patient Program for the Use of Ulocuplumab for the Treatment of Multiple Myeloma
An early-access named-patient program using Ulocuplumab for relapsed multiple myeloma is no longer available.
-
CLINICAL_TRIALS withdrawal · 2017-08-24Clinical Trial Update: Pembrolizumab Cyclophosphamide and Lenalidomide for Patients With Relapsed Multiple Myeloma [Phase 1, Phase 2]
A Phase 1/2 trial evaluating pembrolizumab with cyclophosphamide and lenalidomide for relapsed multiple myeloma has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2017-07-05Clinical Trial Update: GO-203-2C + Bortezomib For Relapsed Or Refractory MM [Phase 1]
A Phase 1 trial of GO-203-2C plus bortezomib for relapsed or refractory multiple myeloma has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2017-06-05Clinical Trial Update: A Study of Venetoclax and ABBV-838 Combination Therapy With Dexamethasone in Participants With Multiple Myeloma Whose Cancer Has Come Back or Had No Response to Recent Cancer Treatment [Phase 1]
This document notes the withdrawal of a Phase 1 clinical trial evaluating a combination of venetoclax and ABBV-838 with dexamethasone in par…
-
CLINICAL_TRIALS withdrawal · 2017-05-31Clinical Trial Update: Detecting Early Myocardial Infiltration w/Amyloid & Light Chain Deposition Disease in Multiple Myeloma Subjects
The clinical trial examining early myocardial infiltration due to amyloid and light chain deposition in multiple myeloma patients has been t…
-
CLINICAL_TRIALS withdrawal · 2017-04-25Clinical Trial Update: Induction Therapy for Multiple Myeloma With Carfilzomib, Lenalidomide,Dexamethasone,Panobinostat [Phase 1, Phase 2]
This clinical trial update indicates withdrawal of a Phase 1/Phase 2 induction therapy trial using carfilzomib, lenalidomide, dexamethasone,…